Medicxi Ventures Management (Jersey) Ltd - Q3 2022 holdings

$240 Million is the total value of Medicxi Ventures Management (Jersey) Ltd's 6 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 16.7% .

 Value Shares↓ Weighting
CNTA SellCENTESSA PHARMACEUTICALS PLCsponsored ads$80,252,000
-58.7%
19,963,157
-50.0%
33.41%
-17.3%
SellAURA BIOSCIENCES INC$55,083,000
-36.1%
3,039,892
-50.0%
22.93%
+28.2%
PCVX SellVAXCYTE INC$45,299,000
-44.9%
1,887,478
-50.0%
18.86%
+10.6%
MRUS SellMERUS N V$32,048,000
-55.8%
1,600,000
-50.0%
13.34%
-11.3%
PHAT SellPHATHOM PHARMACEUTICALS INC$27,526,000
-33.5%
2,484,274
-49.3%
11.46%
+33.4%
OBSV SellOBSEVA SA$0
-100.0%
0
-100.0%
0.00%
-100.0%
CMPI ExitCHECKMATE PHARMACEUTICALS IN$00
+100.0%
0.00%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Francesco De Rubertis #1
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-10-25
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
PHATHOM PHARMACEUTICALS INC16Q3 202369.8%
MERUS N V16Q3 202325.3%
VAXCYTE INC14Q3 202344.5%
OBSEVA SA12Q3 20225.7%
CENTESSA PHARMACEUTICALS PLC10Q3 202371.3%
AURA BIOSCIENCES INC8Q3 202322.9%
CHECKMATE PHARMACEUTICALS IN8Q2 202212.7%
NEWAMSTERDAM PHARMA COMPANY4Q3 202311.4%
SYNTHORX INC1Q4 201943.1%

View Medicxi Ventures Management (Jersey) Ltd's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-04-15
13F-HR2024-02-01
32024-01-26
13F-HR2023-10-18
13F-HR2023-07-19
13F-HR2023-04-27
13F-HR2023-01-31
13F-HR2022-10-25
13F-HR/A2022-08-03
13F-HR2022-08-03

View Medicxi Ventures Management (Jersey) Ltd's complete filings history.

Compare quarters

Export Medicxi Ventures Management (Jersey) Ltd's holdings